NCT02566161 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bouffler SD, Bridges BA, Cooper DN, Dubrova Y, McMillan TJ, Thacker J, Wright EG, Waters R
Assessing radiation-associated mutational risk to the germline: repetitive DNA sequences as mutational targets and biomarkers. Radiat Res. 2006 Mar;165(3):249-68. Review.
Dubrova YE, Grant G, Chumak AA, Stezhka VA, Karakasian AN
Elevated minisatellite mutation rate in the post-chernobyl families from ukraine. Am J Hum Genet. 2002 Oct;71(4):801-9. Epub 2002 Sep 11.
Little MP, Goodhead DT, Bridges BA, Bouffler SD
Evidence relevant to untargeted and transgenerational effects in the offspring of irradiated parents. Mutat Res. 2013 Jul-Sep;753(1):50-67. doi: 10.1016/j.mrrev.2013.04.001. Epub 2013 May 4. Review.

Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)

Clinical trial NCT02566161 - References